Clinical Efficacy and Safety of Nivolumab in Japanese Patients With Malignant Pleural Mesothelioma: 3-Year Results of the MERIT Study

Clinical Efficacy and Safety of Nivolumab in Japanese Patients With Malignant Pleural Mesothelioma: 3-Year Results of the MERIT Study

Introduction: We examined the long-term efficacy and safety of nivolumab, a human monoclonal antibody that inhibits interactions between the programmed cell death protein-1 receptor and its ligands (programmed death-ligand 1 and programmed death-ligand 2), in Japanese patients with malignant pleural...

Full description

Bibliographic Details
Main Authors: Nobukazu Fujimoto, MD, PhD, Morihito Okada, MD, PhD, Takashi Kijima, MD, PhD, Keisuke Aoe, MD, PhD, Terufumi Kato, MD, Kazuhiko Nakagawa, MD, PhD, Yuichiro Takeda, MD, PhD, Toyoaki Hida, MD, PhD, Kuninobu Kanai, MD, PhD, Jun Hirano, MPharm, Yuichiro Ohe, MD, PhD
Format: Article
Language:English
Published: Elsevier 2021-03-01
Series:JTO Clinical and Research Reports
Subjects:
Malignant pleural mesothelioma
Nivolumab
Programmed death-1
Japan
Online Access:http://www.sciencedirect.com/science/article/pii/S2666364320301867

Internet

http://www.sciencedirect.com/science/article/pii/S2666364320301867

Similar Items